- Latest available (Revised)
- Point in Time (27/09/2010)
- Original (As made)
Version Superseded: 28/03/2011
Point in time view as at 27/09/2010.
There are currently no known outstanding effects for the The Misuse of Drugs Regulations 2001.
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
Regulation 3
1. The following substances and products, namely -U.K.
(a)Bufotenine
Cannabinol
Cannabinol derivatives not being dronabinol or its stereoisomers
Cannabis and cannabis resin
Cathinone
Coca leaf
Concentrate of poppy-straw
[F1[2,3–Dihydro–5–methyl–3–(4–morpholinylmethyl)pyrrolo[1, 2, 3–de]–1,4–benzoxazin–6–yl]–1–naphthalenylmethanone]
[F13–Dimethylheptyl–11–hydroxyhexahydrocannabinol]
Eticyclidine
Etryptamine
[F2Fungus (of any kind) which contains psilocin or an ester of psilocin]
[F3[9–Hydroxy–6–methyl–3–[5–phenylpentan–2–yl] oxy–5, 6, 6a, 7, 8, 9, 10, 10a–octahydrophenanthridin–1–yl] acetate]
[F39-(Hydroxymethyl)–6, 6–dimethyl–3–(2–methyloctan–2–yl)–6a, 7, 10, 10a–tetrahydrobenzo[c]chromen–1–ol]
Lysergamide
Lysergide and otherN-alkyl derivatives of lysergamide
Mescaline
Methcathinone
[F44–methylmethcathinone]
Psilocin
Raw opium
Rolicyclidine
Tenocyclidine
4-Bromo-2,5-dimethoxy-a-methylphenethylamine
N,N-Diethyltryptamine
N,N-Dimethyltryptamine
2,5-Dimethoxy-a,4-dimethylphenethylamine
N-Hydroxy-tenamphetamine
4-Methyl-aminorex
(b)any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from tryptamine or from a ring-hydroxy tryptamine by substitution at the nitrogen atom of the sidechain with one or more alkyl substituents but no other substituent;
(c)the following phenethylamine derivatives, namely—
Allyl(a-methyl-3,4-methylenedioxyphenethyl)amine
2-Amino-1-(2,5-dimethoxy-4-methylphenyl)ethanol
2-Amino-1-(3,4-dimethoxyphenyl)ethanol
Benzyl(a-methyl-3,4-methylenedioxyphenethyl)amine
4-Bromo-b,2,5-trimethoxyphenethylamine
N-(4-sec-Butylthio-2,5-dimethoxyphenethyl)hydroxylamine
Cyclopropylmethyl(a-methyl-3,4-methylenedioxyphenethyl)amine
2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)ethylamine
2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)-1-methylethylamine
2-(2,5-Dimethoxy-4-methylphenyl)cyclopropylamine
2-(1,4-Dimethoxy-2-naphthyl)ethylamine
2-(1,4-Dimethoxy-2-naphthyl)-1-methylethylamine
N-(2,5-Dimethoxy-4-propylthiophenethyl)hydroxylamine
2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)ethylamine
2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)-1-methylethylamine
a,a-Dimethyl-3,4-methylenedioxyphenethylamine
a,a-Dimethyl-3,4-methylenedioxyphenethyl(methyl)amine
Dimethyl(a-methyl-3,4-methylenedioxyphenethyl)amine
N-(4-Ethylthio-2,5-dimethoxyphenethyl)hydroxylamine
4-Iodo-2,5-dimethoxy-a-methylphenethyl(dimethyl)amine
2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)ethylamine
2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)-1-methylethylamine
2-(5-Methoxy-2,2-dimethyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine
2-Methoxyethyl(a-methyl-3,4-methylenedioxyphenethyl)amine
2-(5-Methoxy-2-methyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine
b-Methoxy-3,4-methylenedioxyphenethylamine
1-(3,4-Methylenedioxybenzyl)butyl(ethyl)amine
1-(3,4-Methylenedioxybenzyl)butyl(methyl)amine
2-(a-Methyl-3,4-methylenedioxyphenethylamino)ethanol
a-Methyl-3,4-methylenedioxyphenethyl(prop-2-ynyl)amine
N-Methyl-N-(a-methyl-3,4-methylenedioxyphenethyl)hydroxylamine
O-Methyl-N-(a-methyl-3,4-methylenedioxyphenethyl)hydroxylamine
a-Methyl-4-(methylthio)phenethylamine
b,3,4,5-Tetramethoxyphenethylamine
b,2,5-Trimethoxy-4-methylphenethylamine
(d)any compound (not being methoxyphenamine or a compound for the time being specified in sub-paragraph (a) above) structurally derived from phenethylamine, anN-alkylphenethylamine,a-methylphenethylamine, anN-alkyl-a-methylphenethylamine,a-ethylphenethylamine, or anN-alkyl-a-ethylphenethylamine by substitution in the ring to any extent with alkyl, alkoxy, alkylenedioxy or halide substitutents, whether or not further substituted in the ring by one or more other univalent substituents;
(e)any compound (not being a compound for the time being specified in Schedule 2) structurally derived from fentanyl by modification in any of the following ways, that is to say -
(i)by replacement of the phenyl portion of the phenethyl group by any heteromonocycle whether or not further substituted in the heterocycle;
(ii)by substitution in the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halogeno, haloalkyl, amino or nitro groups;
(iii)by substitution in the piperidine ring with alkyl or alkenyl groups;
(iv)by substitution in the aniline ring with alkyl, alkoxy, alkylenedioxy, halogeno or haloalkyl groups;
(v)by substitution at the 4-position of the piperidine ring with any alkoxycarbonyl or alkoxyalkyl or acyloxy group;
(vi)by replacement of theN-propionyl group by another acyl group;
(f)any compound (not being a compound for the time being specified in Schedule 2) structurally derived from pethidine by modification in any of the following ways, that is to say—
(i)by replacement of the l-methyl group by an acyl, alkyl whether or not unsaturated, benzyl or phenethyl group, whether or not further substituted;
(ii)by substitution in the piperidine ring with alkyl or alkenyl groups or with a propano bridge, whether or not further substituted;
(iii)by substitution in the 4-phenyl ring with alkyl, alkoxy, aryloxy, halogeno or haloalkyl groups;
(iv)by replacement of the 4-ethoxycarbonyl by any other alkoxycarbonyl or any alkoxyalkyl or acyloxy group;
(v)by formation of an N-oxide or of a quaternary base.
[F5(g)1–benzylpiperazine or any compound (not being a compound for the time being specified in Schedule 4) structurally derived from 1–benzylpiperazine or 1–phenylpiperazine by modification in any of the following ways—
(i)by substitution at the second nitrogen atom of the piperazine ring with alkyl, benzyl, haloalkyl or phenyl groups;
(ii)by substitution in the aromatic ring to any extent with alkyl, alkoxy, alkylenedioxy, halide or haloalkyl groups;
(h)any compound structurally derived from 3–(1–naphthoyl)indole or 1H–indol–3–yl–(1–naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent;
(i)any compound structurally derived from 3–(1–naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent;
(j)any compound structurally derived from 1–(1–naphthylmethyl)indene by substitution at the 3–position of the indene ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent;
(k)any compound structurally derived from 3–phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent;
(l)any compound structurally derived from 2–(3–hydroxycyclohexyl)phenol by substitution at the 5–position of the phenolic ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the cyclohexyl ring to any extent.]
[F6(m)Any compound (not being bupropion, diethylpropion, pyrovalerone or a compound for the time being specified in sub–paragraph (a) above) structurally derived from 2–amino–1–phenyl–1–propanone by modification in any of the following ways, that is to say—
(i)by substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents;
(ii)by substitution at the 3–position with an alkyl substituent;
(iii)by substitution at the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure.]
[F7(n)Any compound structurally derived from 2–aminopropan–1–one by substitution at the 1‑position with any monocyclic, or fused‑polycyclic ring system (not being a phenyl ring or alkylenedioxyphenyl ring system), whether or not the compound is further modified in any of the following ways, that is to say—
(i)by substitution in the ring system to any extent with alkyl, alkoxy, haloalkyl or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents;
(ii)by substitution at the 3–position with an alkyl substituent;
(iii)by substitution at the 2‑amino nitrogen atom with alkyl or dialkyl groups, or by inclusion of the 2‑amino nitrogen atom in a cyclic structure.]
Textual Amendments
F1Words in Sch. 1 para. 1(a) inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(1)(a)(i)
F2Words in Sch. 1 para. 1(a) inserted (18.7.2005) by The Misuse of Drugs (Amendment) (No. 2) Regulations 2005 (S.I. 2005/1653), regs. 1, 2(3)
F3Words in Sch. 1 para. 1(a) inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(1)(a)(ii)
F4Words in Sch. 1 para. 1(a) inserted (16.4.2010) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2010 (S.I. 2010/1144), regs. 1(1), 3(a)
F5Sch. 1 para. 1(g)-(l) inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(1)(b)
F6Sch. 1 para. 1(m) inserted (16.4.2010) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2010 (S.I. 2010/1144), regs. 1(1), 3(b)
2. Any stereoisomeric form of a substance specified in paragraph 1.U.K.
3. Any ester or ether of a substance specified in paragraph 1 or 2.U.K.
4. Any salt of a substance specified in any of paragraphs 1 to 3.U.K.
5. Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 4, not being a preparation specified in Schedule 5.U.K.
Regulation 3
1. The following substances and products, namely—U.K.
Acetorphine
Alfentanil
Allylprodine
Alphacetylmethadol
Alphameprodine
Alphamethadol
Alphaprodine
Anileridine
Benzethidine
Benzylmorphine (3-benzylmorphine)
Betacetylmethadol
Betameprodine
Betamethadol
Betaprodine
Bezitramide
Carfentanil
Clonitazene
Cocaine
Desomorphine
Dextromoramide
Diamorphine
Diampromide
Diethylthiambutene
Difenoxin
Dihydrocodeinone O-carboxymethyloxime
[F8Dihydroetorphine]
Dihydromorphine
Dimenoxadole
Dimepheptanol
Dimethylthiambutene
Dioxaphetyl butyrate
Diphenoxylate
Dipipanone
Dronabinol
Drotebanol
Ecgonine, and any derivative of ecgonine which is convertible to ecgonine or to cocaine
Ethylmethylthiambutene
Etonitazene
Etorphine
Etoxeridine
Fentanyl
Furethidine
Hydrocodone
Hydromorphinol
Hydromorphone
Hydroxypethidine
Isomethadone
Ketobemidone
Levomethorphan
Levomoramide
Levophenacylmorphan
Levorphanol
Lofentanil
Medicinal opium
Metazocine
Methadone
Methadyl acetate
Methyldesorphine
Methyldihydromorphine (6-methyldihydromorphine)
Metopon
Morpheridine
Morphine
Morphine methobromide, morphine N-oxide and other pentavalent nitrogen morphine derivatives
Myrophine
[F9Nabilone]
Nicomorphine
Noracymethadol
Norlevorphanol
Normethadone
Normorphine
Norpipanone
[F10Oripavine]
Oxycodone
Oxymorphone
Pethidine
Phenadoxone
Phenampromide
Phenazocine
Phencyclidine
Phenomorphan
Phenoperidine
Piminodine
Piritramide
Proheptazine
Properidine
Racemethorphan
Racemoramide
Racemorphan
[F11Remifentanil]
Sufentanil
Thebacon
Thebaine
Tilidate
Trimeperidine
Zipeprol
4-Cyano-2-dimethylamino-4,4-diphenylbutane
4-Cyano-1-methyl-4-phenylpiperidine
2-Methyl-3-morpholino-1,1-diphenylpropane-carboxylic acid
a-Methylphenethylhydroxylamine
1-Methyl-4-phenylpiperidine-4-carboxylic acid
4-Phenylpiperidine-4-carboxylic acid ethyl ester
Textual Amendments
F8Word in Sch. 2 para. 1 inserted (1.7.2003) by The Misuse of Drugs (Amendment) Regulations 2003 (S.I. 2003/1432), regs. 1, 2(2)(a)
F9Word in Sch. 2 para. 1 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(2)(a)
F10Word in Sch. 2 para. 1 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(2)(b)
F11Word in Sch. 2 para. 1 inserted (1.7.2003) by The Misuse of Drugs (Amendment) Regulations 2003 (S.I. 2003/1432), regs. 1, 2(2)(b)
2. Any stereoisomeric form of a substance specified in paragraph 1 not being dextromethorphan or dextrorphan.U.K.
3. Any ester or ether of a substance specified in paragraph 1 or 2, not being a substance specified in paragraph 6.U.K.
4. Any salt of a substance specified in any of paragraphs 1 to 3.U.K.
5. Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 4, not being a preparation specified in Schedule 5.U.K.
6. The following substances and products, namely—U.K.
Acetyldihydrocodeine | Methaqualone |
Amphetamine | Methylamphetamine |
Codeine | Methylphenidate |
Dextropropoxyphene | Nicocodine |
Dihydrocodeine | Nicodicodine (6-nicotinoyldihydrocodeine) |
Ethylmorphine (3-ethylmorphine) | Norcodeine |
Fenethylline | Phenmetrazine |
Glutethimide | Pholcodine |
Lefetamine | Propiram |
Mecloqualone | Quinalbarbitone |
7. Any stereoisomeric form of a substance specified in paragraph 6.U.K.
8. Any salt of a substance specified in paragraph 6 or 7.U.K.
9. Any preparation or other product containing a substance or product specified in any of paragraphs 6 to 8, not being a preparation specified in Schedule 5.U.K.
Regulation 3
1. The following substances, namely—U.K.
(a)
Benzphetamine
Buprenorphine
Cathine
Chlorphentermine
Diethylpropion
Ethchlorvynol
Ethinamate
Flunitrazepam
Mazindol
Mephentermine
Meprobamate
Methylphenobarbitone
Methyprylone
[F12Midazolam]
Pentazocine
Phendimetrazine
Phentermine
Pipradrol
Temazepam
(b)any 5, 5 disubstituted barbituric acid not being quinalbarbitone.
Textual Amendments
F12Word in Sch. 3 para. 1(a) inserted (1.1.2008) by The Misuse of Drugs and Misuse of Drugs (Safe Custody) (Amendment) Regulations 2007 (S.I. 2007/2154), regs. 2(3)(e), 4(14)
2. Any stereoisomeric form of a substance specified in paragraph 1 not being phenylpropanolamine.U.K.
3. Any salt of a substance specified in paragraph 1 or 2.U.K.
4. Any preparation or other product containing a substance specified in any of paragraphs 1 to 3, not being a preparation specified in Schedule 5.U.K.
Regulation 3
1. The following substances and products, namely—U.K.
Alprazolam
Aminorex
Bromazepam
Brotizolam
Camazepam
Chlordiazepoxide
[F131–(3–chlorophenyl)piperazine]
[F131–(3–chlorophenyl)–4–(3–chloropropyl)piperazine]
Clobazam
Clonazepam
Clorazepic acid
Clotiazepam
Cloxazolam
Delorazepam
Diazepam
Estazolam
Ethyl loflazepate
Fencamfamin
Fenproporex
Fludiazepam
Flurazepam
Halazepam
Haloxazolam
[F144-Hydroxy-n-butyric acid]
[F15Ketamine]
Ketazolam
Loprazolam
Lorazepam
Lormetazepam
Medazepam
Mefenorex
Mesocarb
F16...
Nimetazepam
Nitrazepam
Nordazepam
Oxazepam
Oxazolam
Pemoline
Pinazepam
Prazepam
Pyrovalerone
Tetrazepam
Triazolam
N-Ethylamphetamine
[F17Zolpidem]
Textual Amendments
F13Words in Sch. 4 Pt. 1 para. 1 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(3)
F14Words in Sch. 4 Pt. 1 para. 1 inserted (1.7.2003) by The Misuse of Drugs (Amendment) Regulations 2003 (S.I. 2003/1432), regs. 1, 2(3)(a)
F15Word in Sch. 4 Pt. 1 para. 1 inserted (1.1.2006) by The Misuse of Drugs (Amendment) (No. 3) Regulations 2005 (S.I. 2005/3372), regs. 1, 2
F16Word in Sch. 4 Pt. 1 para. 1 omitted (1.1.2008) by virtue of The Misuse of Drugs and Misuse of Drugs (Safe Custody) (Amendment) Regulations 2007 (S.I. 2007/2154), regs. 2(3)(e), 4(13)
F17Word in Sch. 4 Pt. 1 para. 1 inserted (1.7.2003) by The Misuse of Drugs (Amendment) Regulations 2003 (S.I. 2003/1432), regs. 1, 2(3)(b)
2. Any stereoisomeric form of a substance specified in paragraph 1.U.K.
3. Any salt of a substance specified in paragraph 1 or 2.U.K.
4. Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 3, not being a preparation specified in Schedule 5.U.K.
1. The following substances, namely—U.K.
[F185α–Androstane–3,17–diol]
[F18Androst-4-ene-3,17-diol]
[F181–Androstenediol]
[F181–Androstenedione]
[F194-Androstene-3, 17-dione]
[F205–Androstenedione]
[F195-Androstene-3, 17 diol]
Atamestane
Bolandiol
Bolasterone
Bolazine
Boldenone
[F21Boldione]
Bolenol
Bolmantalate
Calusterone
4-Chloromethandienone
Clostebol
[F22Danazol]
[F22Desoxymethyltestosterone]
Drostanolone
Enestebol
Epitiostanol
Ethyloestrenol
Fluoxymesterone
Formebolone
Furazabol
[F23Gestrinone]
[F233–Hydroxy–5α–androstan–17–one]
Mebolazine
Mepitiostane
Mesabolone
Mestanolone
Mesterolone
Methandienone
Methandriol
Methenolone
Methyltestosterone
Metribolone
Mibolerone
Nandrolone
[F2419–Norandrostenedione]
[F2519-Nor-4-Androstene-3, 17-dione]
[F2519-Nor-5-Androstene-3, 17 diol]
[F2619–Norandrosterone]
Norboletone
Norclostebol
Norethandrolone
[F2719–Noretiocholanolone]
Ovandrotone
Oxabolone
Oxandrolone
Oxymesterone
Oxymetholone
Prasterone
Propetandrol
[F28Prostanozol]
Quinbolone
Roxibolone
Silandrone
Stanolone
Stanozolol
Stenbolone
Testosterone
[F29Tetrahydrogestrinone]
Thiomesterone
Trenbolone
Textual Amendments
F18Words in Sch. 4 Pt. 2 para. 1 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(4)(a)(i)
F19Words in Sch. 4 Pt. 2 para. 1 inserted (1.7.2003) by The Misuse of Drugs (Amendment) Regulations 2003 (S.I. 2003/1432), regs. 1, 2(4)(a)
F20Words in Sch. 4 Pt. 2 para. 1 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(4)(a)(ii)
F21Words in Sch. 4 Pt. 2 para. 1 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(4)(a)(iii)
F22Words in Sch. 4 Pt. 2 para. 1 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(4)(a)(iv)
F23Words in Sch. 4 Pt. 2 para. 1 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(4)(a)(v)
F24Words in Sch. 4 Pt. 2 para. 1 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(4)(a)(vi)
F25Words in Sch. 4 Pt. 2 para. 1 inserted (1.7.2003) by The Misuse of Drugs (Amendment) Regulations 2003 (S.I. 2003/1432), regs. 1, 2(4)(b)
F26Words in Sch. 4 Pt. 2 para. 1 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(4)(a)(vii)
F27Words in Sch. 4 Pt. 2 para. 1 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(4)(a)(viii)
F28Words in Sch. 4 Pt. 2 para. 1 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(4)(a)(ix)
F29Words in Sch. 4 Pt. 2 para. 1 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(4)(a)(x)
2. Any compound (not being Trilostane or a compound for the time being specified in paragraph 1 of this Part of this Schedule) structurally derived from 17-hydroxyandrostan-3-one or from 17-hydroxyestran-3-one by modification in any of the following ways, that is to say -U.K.
(a)by further substitution at position 17 by a methyl or ethyl group;
(b)by substitution to any extent at one or more of positions 1, 2, 4, 6, 7, 9, 11 or 16, but at no other position;
(c)by unsaturation in the carbocyclic ring system to any extent, provided that there are no more than two ethylenic bonds in any one carbocyclic ring;
(d)by fusion of ring A with a heterocyclic system.
3. Any substance which is an ester or ether (or, where more than one hydroxyl function is available, both an ester and an ether) of a substance specified in paragraph 1 or described in paragraph 2 of this Part of this Schedule.U.K.
4. The following substances, namely—U.K.
Chorionic Gonadotrophin (HCG)
Clenbuterol
Non-human chorionic gonadotrophin
Somatotropin
Somatrem
Somatropin
[F30Zeranol]
[F30Zilpaterol]
Textual Amendments
F30Words in Sch. 4 Pt. 2 para. 4 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(4)(b)
5. Any stereoisomeric form of a substance specified or described in any of paragraphs 1 to 4 of this Part of this Schedule.U.K.
6. Any salt of a substance specified or described in any of paragraphs 1 to 5 of this Part of this Schedule.U.K.
7. Any preparation or other product containing a substance or product specified or described in any of paragraphs 1 to 6 of this Part of this Schedule, not being a preparation specified in Schedule 5.U.K.
Regulation 3
1.—(1) Any preparation of one or more of the substances to which this paragraph applies, not being a preparation designed for administration by injection, when compounded with one or more other active or inert ingredients and containing a total of not more than 100 milligrams of the substance or substances (calculated as base) per dosage unit or with a total concentration of not more than 2.5% (calculated as base) in undivided preparations.U.K.
(2) The substances to which this paragraph applies are acetyldihydrocodeine, codeine, dihydrocodeine, ethylmorphine, nicocodine, nicodicodine (6-nicotinoyldihydrocodeine), norcodeine and pholcodine and their respective salts.
F312. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .U.K.
Textual Amendments
3. Any preparation of medicinal opium or of morphine containing (in either case) not more than 0.2% of morphine calculated as anhydrous morphine base, being a preparation compounded with one or more other active or inert ingredients in such a way that the opium or, as the case may be, the morphine cannot be recovered by readily applicable means or in a yield which would constitute a risk to health.U.K.
4. Any preparation of dextropropoxyphene, being a preparation designed for oral administration, containing not more than 135 milligrams of dextropropoxyphene (calculated as base) per dosage unit or with a total concentration of not more than 2.5% (calculated as base) in undivided preparations.U.K.
5. Any preparation of difenoxin containing, per dosage unit, not more than 0.5 milligrams of difenoxin and a quantity of atropine sulphate equivalent to at least 5% of the dose of difenoxin.U.K.
6. Any preparation of diphenoxylate containing, per dosage unit, not more than 2.5 milligrams of diphenoxylate calculated as base, and a quantity of atropine sulphate equivalent to at least 1% of the dose of diphenoxylate.U.K.
7. Any preparation of propiram containing, per dosage unit, not more than 100 milligrams of propiram calculated as base and compounded with at least the same amount (by weight) of methylcellulose.U.K.
8. Any powder of ipecacuanha and opium comprising—U.K.
10% opium, in powder,
10% ipecacuanha root, in powder, well mixed with
80% of any other powdered ingredient containing no controlled drug.
9. Any mixture containing one or more of the preparations specified in paragraphs 1 to 8, being a mixture of which none of the other ingredients is a controlled drug.U.K.
Regulation 19
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Textual Amendments
Regulation 28
Regulations revoked | References |
---|---|
The Misuse of Drugs Regulations 1985 | S.I. 1985/2066 |
The Misuse of Drugs (Amendment) Regulations 1986 | S.I. 1986/2330 |
The Misuse of Drugs (Amendment) Regulations 1988 | S.I. 1988/916 |
The Misuse of Drugs (Amendment) Regulations 1989 | S.I. 1989/1460 |
The Misuse of Drugs (Amendment) Regulations 1990 | S.I. 1990/2630 |
The Misuse of Drugs (Amendment) Regulations 1995 | S.I. 1995/2048 |
The Misuse of Drugs (Amendment No. 2) Regulations 1995 | S.I. 1995/3244 |
The Misuse of Drugs (Amendment) Regulations 1996 | S.I. 1996/1597 |
The Misuse of Drugs (Amendment) Regulations 1998 | S.I. 1998/882 |
The Misuse of Drugs (Amendment) Regulations 1999 | S.I. 1999/1404 |
Regulations 8(8) and 9(8)
Textual Amendments
F33Sch. 8 inserted (15.10.2003) by The Misuse of Drugs (Amendment) (No. 3) Regulations 2003 (S.I. 2003/2429), reg. 1, Sch.
1. Any of the following persons may supply or administer a specified controlled drug under a patient group direction, namely—U.K.
(a)a person who holds a certificate of proficiency in ambulance paramedic skills issued by, or with the approval of, the Secretary of State, or a person who is a F34... registered paramedic;
F35(b). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(c)a registered midwife;
[F36(d)a registered optometrist;
(e)a registered chiropodist;
(f)a registered orthoptist;
(g)a registered physiotherapist;
(h)a registered radiographer;]
[F37(i)a registered occupational therapist;
(j)a registered orthotist and prosthetist;]]
Textual Amendments
F34Word in Sch. 8 para. 1(a) revoked (16.8.2007) by The Misuse of Drugs and Misuse of Drugs (Safe Custody) (Amendment) Regulations 2007 (S.I. 2007/2154), regs. 2(1), 4(16)(a)
F35Sch. 8 para. 1(b) omitted (1.8.2004) by virtue of The Health Act 1999 (Consequential Amendments) (Nursing and Midwifery) Order 2004 (S.I. 2004/1771), art. 1(1), Sch. para. 24(d)
F36Sch. 8 para. 1(d)-(h) substituted (16.8.2007) by The Misuse of Drugs and Misuse of Drugs (Safe Custody) (Amendment) Regulations 2007 (S.I. 2007/2154), regs. 2(1), 4(16)(b)
F37Sch. 8 para. 1(i)(j) inserted (7.7.2006) by The Misuse of Drugs (Amendment No. 2) Regulations 2006 (S.I. 2006/1450), regs. 2(1), 11 (with regs. 12, 13)
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: